ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 2233 • ACR Convergence 2024

    Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Susan Manzi5, Michael Mahler6, Veena Joy7 and Tyler O'Malley8, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Werfen, San Diego, CA, 7ThermoFisher, Philadelphia, PA, 8Exagen, Vista, CA

    Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
  • Abstract Number: 0055 • ACR Convergence 2024

    Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis

    Katharine moosic1, Thomas Olson2, Mark Freijat3, samara khalique4, Cait Hamele1, Bryna Shemo1, Jesse Boodoo5, William Baker6, Gitanjali Khurana7, Matthew Schmachtenberg8, Tristin Duffy8, Aakrosh Ratan1, Erika Darrah9, Felipe Andrade10, Marieke Jones8, Kristine Olson2, David Feith1, Thomas Loughran1 and Donald Kimpel1, 1University of Virginia, Charlottesville, VA, 2Virginia Commonwealth University, Richmond, VA, 3Flow Rheumatology, Scottsdale, AZ, 4Carilion Clinic/ VirginiaTech, Salem, VA, 5Sarasota Arthritis Center, Sarasota, FL, 6Atrium Health, Charlotte, NC, 7University of Virginia, CROZET, VA, 8University of Virginia, Charlottesville, 9Johns Hopkins University, Baltimore, MD, 10The Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
  • Abstract Number: 2250 • ACR Convergence 2024

    Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity

    Elena Joerns1, Ryan Lennon2, Cynthia Crowson2, Andrea Lopez-ruiz2, Roslin Jose George2, Vanessa Kronzer2, John Davis2 and Elena Myasoedova2, 1Mayo Clinic, Rochester, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
  • Abstract Number: 0059 • ACR Convergence 2024

    Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance

    Susanna R. Bidgood1, Sophie Hopkin1, Kathryn R. Malpas1, David M. Kallenberg1, Jacqueline O’Neill1, Geofrey Odede1, Bernard Lauwerys2, Baran Ufuktepe3 and David Humphreys1, 1UCB Biopharma UK, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Istanbul, Turkey

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
  • Abstract Number: 2266 • ACR Convergence 2024

    Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis

    Michael George1, Kelly Gavigan2, Shilpa Venkatachalam3, David Curtis2, Laura Stradford4, William Benjamin Nowell5, Fenglong Xie6, Joshua Baker1 and Jeffrey Curtis7, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, New York, NY, 4Global Healthy Living Foundation, Nyack, NY, 5Regeneron, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…
  • Abstract Number: 0158 • ACR Convergence 2024

    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023

    Karis Lee1, Min Kyung Lee2, David Alfego3, Kristen Clark4 and Stanley Naides5, 1Labcorp, Orlando, FL, 2Labcorp, San Diego, CA, 3Labcorp, Carlsbad, CA, 4Labcorp, Raleigh, NC, 5Labcorp, Dana Point, CA

    Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
  • Abstract Number: 2286 • ACR Convergence 2024

    Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials

    Josef Smolen1, Gerd Burmester2, Yoshiya Tanaka3, Tsutomu Takeuchi4, Jeffrey Curtis5, Ted Mikuls6, Clementina López Medina7, Peter C. Taylor8, Nicola Tilt9, Bernard Lauwerys10, Baran Ufuktepe11 and Thomas Huizinga12, 1Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 4Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 5The University of Alabama at Birmingham, Birmingham, AL, 6University of Nebraska Medical Center, Omaha, NE, 7Reina Sofia University Hospital, Cordoba, Spain, 8University of Oxford, Oxford, United Kingdom, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Brussels, Belgium, 11UCB Pharma, Istanbul, Turkey, 12Department of Rheumatology, Leiden University, Leiden, Netherlands

    Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
  • Abstract Number: 0458 • ACR Convergence 2024

    Long-Term Outcomes in Seronegative Rheumatoid Arthritis

    Bradly Kimbrough1, Cynthia Crowson2, Sara Achenbach3 and Elena Myasoedova2, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
  • Abstract Number: 2302 • ACR Convergence 2024

    A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma

    Jing Jing Wang1, Bridie Armour1, Alexander Troelnikov1, Tim Chataway1, Veronique LE GUERN2, Eric Hachulla3, Alain SARAUX4, Claire Larroche5, Jacques-Eric Gottenberg6, Xavier Mariette7 and Gaetane Nocturne7, 1Flinders University, Adeleide, Australia, 2Cochin hospital, Paris, France, 3University of Lille, LILLE, France, 4CHU Brest, Brest, France, 5Avicenne University Hospital, Avicenne, France, 6Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 7Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Sjogren’s disease (SjD) is characterized by an increased risk of lymphoma (x 10-15 compared to the general population). We and others have previously demonstrated…
  • Abstract Number: 0475 • ACR Convergence 2024

    Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Libe Ibarrola Paino3, Ivette Casafont-Sole4, Jesús Loarce5, Juan María Blanco Madrigal6, Santos Castañeda7, Rafaela Ortega-Castro8, Natalia Mena Vázquez9, Nuria Vegas Revenga10, Lucia Cristina Dominguez Casas11, Cilia Peralta Ginés12, Carolina Diez Morrondo13, Lorena Pérez Albadalejo14, Rubén López Sánchez15, MARIA GUADALUPE MANZANO CANABAL16, Anahy Maria Brandy-Garcia17, Patricia Lopez Viejo18, Gema Bonilla19, Olga Maíz Alonso20, Carmen Carrasco-Cubero21, Marta Garijo Bufort22, Mireia Moreno Martinez-Losa23, Ana Urruticoechea-Arana24, Sergi Ordoñez25, Carmen González Montagut26, Andrea García-Valle27, Juan Ramón De Dios28, Patricia Carreira29, Tomás Vázquez Rodríguez30, Delia Fernández-Lozano31, Ignacio Brana Abascal32, Rafael Benito Melero-Gonzalez33, Emilio Giner34, Virginia Ruiz Esquide35, Clara Ventin Rodriguez36, Marina Rodriguez37, Pablo Andújar-Brazal38, Julia Fernandez Melon39, Lilian M. López-Núñez40, JOSE RAMON LAMUA RIAZUELO41, Carlos Fernández Díaz42, Javier Loricera43 and Ricardo Blanco-Alonso44, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 6Basurto University Hospital, Bilbao, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Hospital Reina Sofía, Cordoba, Andalucia, Spain, 9IBIMA, Málaga, Andalucia, Spain, 10Hospital Galdakao- Usansolo, Galdakao, Spain, 11Hospital Universtario San Agustin, Oviedo, Spain, 12Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 13Hospital de Leon, León, Spain, 14Hospital Universitario de Jaén, Jaén, Spain, 15Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, 16CAZA, Salamanca, Spain, 17Hospital Germans Trias i Pujol, Badalona, Spain, 18Hospital Severo Ochoa, Madrid, Madrid, Spain, 19H. Universitario La Paz, Madrid, Spain, 203Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 21Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 22Hospital de Sagunto, Valencia, Spain, 23Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 24Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, 25Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, 26Hospital Universitario de Valladolid, Valladolid, Spain, 27Hospital General Río Carrión, Palencia, Spain, 28Osakidetza, Vitoria, Spain, 29Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 30Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, 31Hospital Clínico Universitario de Valencia, Valencia, Spain, 32Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 33CHU Ourense, O Carballino, Spain, 34Hospital Royo Villanova, Teruel, Spain, 35Hospital Clinic Barcelona, Barcelona, Spain, 36Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 37Hospital Clínico Universitario de Santiago, La Coruna, Spain, 38Hospital Universitario Doctor Peset, Valencia, Spain, 39Hospital Son Espases, Palma, Spain, 40Hospital Universitari Son Llàtzer, Palma, Spain, 41Hospital Universitario del Henares, Madrid, Spain, 42Hospital Universitario Santa Lucía, Cartagena, Spain, 43Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 44Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
  • Abstract Number: 2671 • ACR Convergence 2024

    Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial

    Michael Weinblatt1, Paul Emery2, Vivian Bykerk3, Andrew Cope4, Gerd Burmester5, Yoshiya Tanaka6, Gustavo Citera7, Peter Nash8, Quentin Dornic9, Sheila Kelly10 and Michael Maldonado9, 1Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 2University of Leeds, Leeds, United Kingdom, 3Hospital For Special Surgery, New York, NY, 4King's College London, London, United Kingdom, 5Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 7Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 8Griffith University, Brisbane, Australia, 9Bristol Myers Squibb, Princeton, NJ, 10Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: For patients (pts) early in their RA disease course, with a clinical profile characterized by inadequate response to MTX (MTX-IR), high titers of ACPA…
  • Abstract Number: 0488 • ACR Convergence 2024

    Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

    Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
  • Abstract Number: 0498 • ACR Convergence 2024

    ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Jacob Welch1, Yangyuna Yang1, Joshua Baker2, Katherine Wysham3, Dana Ascherman4, Paul Monach5, Gail Kerr6, Andreas Reimold7, grant Cannon8, Gary Kunkel9, William Robinson10, Michael Duryee1, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5VA Boston Healthcare System, Boston, MA, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7Dallas VA Medical Center, Dallas, TX, 8University of Utah and Salt Lake City VA, Salt Lake City, UT, 9University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 10Stanford University, Palo Alto, CA

    Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
  • Abstract Number: 0511 • ACR Convergence 2024

    Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial

    Josef Smolen1, Ted Mikuls2, James Galloway3, Ulf Müller-Ladner4, Jeffrey Curtis5, Motomu Hashimoto6, Tsutomu Takeuchi7, Ernest Choy8, Yoshiya Tanaka9, Carlos Cara10, Bernard Lauwerys11, Nicola Tilt12, Baran Ufuktepe13 and Peter C. Taylor14, 1Medical University of Vienna, Vienna, Austria, 2University of Nebraska Medical Center, Omaha, NE, 3Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 4Justus-Liebig University Giessen, Bad Nauheim, Germany, 5University of Alabama at Birmingham, Hoover, AL, 6Osaka Metropolitan University, Osaka, Japan, 7Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 8Cardiff University School of Medicine, Cardiff, United Kingdom, 9Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 10UCB Pharma, Madrid, Spain, 11UCB Pharma, Brussels, Belgium, 12UCB Pharma, Slough, United Kingdom, 13UCB Pharma, Istanbul, Turkey, 14University of Oxford, Oxford, United Kingdom

    Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
  • Abstract Number: 0777 • ACR Convergence 2024

    Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients

    Theodoros Ioannis Papadimitriou1, Jing Jing Wang2, Xuehui He3, Sidney van der Zade4, Massis Krekorian5, Prashant Singh6, Erik Dik5, Ger Pruijn5, Tom Gordon2, Hans Koenen7, Martijn Huijnen8 and Rogier Thurlings1, 1Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, 2Flinders University, Adeleide, Australia, 3Radboudumc, Nijmegen, Netherlands, 4Radboudumc, Amsterdam, Netherlands, 5Radboudumc, Nijmegen, Gelderland, Netherlands, 6Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, 7Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, 8Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology